- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02318901
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab)
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
Study Overview
Status
Intervention / Treatment
Detailed Description
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Pembrolizumab will be infused prior to the start of the assigned monoclonal antibody (Mab) arm. .
Dosing for the Mab arms will begin as follows:
Arm 1: Cycle length is 21 days. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
Arm 2: Cycle length is 21 days. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
Arm 3: Cycle length is 21 days. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
- Western Regional Medical Center/Cancer Treatment Center of America
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has definitive histologically or cytologically confirmed unresectable or metastatic solid tumor.
- Patient has one or more tumor measurable as defined by RECIST 1.1 by CT scan (or PET/CT, if patient is allergic to CT contrast media).
- Patients can be enrolled only on one of the treatment arms on this trial.
- The investigator will select the appropriate treatment arm for the patient with the following requirements: (a) Patients cannot have had prior progression or intolerance to a specific Mab and then enrolled on an arm with that same Mab plus pembro, (b) The Mab on the arm selected must be considered standard of care or listed in the NCCN guidelines (www.nccn.org) for that cancer type. For Arm 1, patients with HER2 overexpressing MBC eligible for maintenance trastuzumab are allowed after taxane plus trastuzumab plus pertuzumab combination therapy.
Have recovered from acute toxicities of prior treatment:
- > 3 weeks must have elapsed since receiving any investigational agent.
- > 2 weeks must have elapsed since receiving any radiotherapy, or ≥ 3 weeks or 5 half-lives whichever is shorter for treatment with cytotoxic or biologic agents ( ≥ 6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.
- Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:
- Absolute neutrophil count (ANC) > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 9 g/dL.
- Serum creatinine ≤2.0, total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal (ULN) range
- Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable.
- Persistent prior systemic therapy non-hematologic AE grade ≥ 2 (except alopecia or correctable electrolyte abnormality with supplementation)
- Patient has a Karnofsky performance status (KPS) ≥ 70.
- Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
Inclusion criteria for Phase II only:
- Patients must have unresectable HER2 overexpressing gastric or GEJ cancers to be enrolled on Cohort 1 of the pembro plus trastuzumab phase II portion.
- Patients must have HER2 overexpressing MBC to be enrolled on Cohort 2 of the pembro plus trastuzumab phase II portion.
- Patients must have HER2 overexpressing MBC to be enrolled on pembro plus ado-trastuzumab emtansine phase II portion.
- Patients must have HNSCC to be enrolled on Cohort 1 of the pembro plus cetuximab phase II portion.
- Patients must have K-ras, B-raf, N-ras wildtype CRC to be enrolled on Cohort 2 of the pembro plus cetuximab phase II portion.
Exclusion Criteria:
- Active clinically serious infection > CTCAE (version 4.03) Grade 2.
- Serious non-healing wound, ulcer, or bone fracture.
- Patient has known brain metastases, unless previously treated and well-controlled for at least 1 month (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
- Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
- Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
- Requiring daily corticosteroid dose ≥ 10 mg prednisone or equivalent per day.
- Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
- Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindication or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information.
- Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
- Patient will be receiving any other anti-cancer therapy during participation in this trial.
- Prior treatment with pembro. Receipt of other PD-1 inhibitors or PD-L1 inhibitors is allowed.
- Active or prior documented autoimmune disease requiring systemic treatment within the past 2 years.
Exclusion Criteria for phase II portion only:
1. Patients with a history of more than one primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the 2 years prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks.
Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
|
Other Names:
Other Names:
|
Experimental: Arm 2
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks.
i.v.
ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
|
Other Names:
Other Names:
|
Experimental: Arm 3
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks.
i.v.
cetuximab 400 mg/m2 on cycle 1 day 1, then i.v.
cetuximab 250 mg/m2 on day 8.
Each subsequent cycle will be i.v.
cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the Recommended Phase 2 Dose (RP2D) of Monoclonal Antibody Therapy (Mab) in Combination With Pembrolizumab (Pembro) in Subjects With Advanced Cancer
Time Frame: 3 weeks
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Grade 3 or Higher Treatment-related Adverse Events by CTCAE 4.03
Time Frame: up to 12 months
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
up to 12 months
|
Response Rate by irRC and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria
Time Frame: 12 weeks
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
12 weeks
|
To Determine the Overall Survival (OS) and Progression-free Survival (PFS)
Time Frame: up to 12 months
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
up to 12 months
|
To Characterize Changes in Circulating Tumor DNA in Patients Enrolled on This Study
Time Frame: up to 12 months
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
up to 12 months
|
Textural Changes Identified on Imaging That is Done Per Routine Practice
Time Frame: 12 weeks
|
PI left site.
Study was prematurely terminated.
No additional study items were conducted including, data collection, results or statistical analysis completed.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jordan Waypa, FNP, Western Regional Medical Center
- Principal Investigator: Alan Tan, MD, Western Regional Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PembroMab
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted